The combination of a lung cancer vaccine plus chemotherapy has been proven to help more patients live without their cancer progressing than chemotherapy alone, a study has revealed.

The research, led by the University of Strasbourg, involved 148 patients with non-small-cell lung cancer, the most common form of the disease.

Results published in The Lancet Oncology showed that 43% of the 74 patients treated with Trasgene’s TG4010 vaccine in combination with chemotherapy survived for six months without the disease progressing, while the progression-free survival rate in the 74 patients treated with chemotherapy alone was 35%.

TG4010 is designed to trigger the immune system and target the MUC1 protein, which is overproduced by tumour cells in advanced lung cancer.

France-based gene therapy group Transgene funded the phase IIb trial.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now